Piper Sandler analyst Christopher Raymond raised the firm’s price target on AbbVie (ABBV) to $220 from $212 and keeps an Overweight rating on the shares. The firm is increasing its Skyrizi and Rinvoq estimates and price target following insights from proprietary survey data with its partners at Spherix, showing meaningful tailwinds for both products in the IBD space.
